Geron (GERN) Net Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Geron (GERN) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 349.49% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -55.11% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 172.72% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 53.21% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 47.11% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -100.75% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,371.48% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -2.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.31% |
| Mar 31, 2026 | -282.89% |
| Dec 31, 2025 | -102.91% |
| Sep 30, 2025 | 100.56% |
| Jun 30, 2025 | 91.74% |
| Mar 31, 2025 | -96.06% |
| Dec 31, 2024 | -53.13% |
| Sep 30, 2024 | -113.44% |
| Jun 30, 2024 | -30.67% |
| Mar 31, 2024 | 114.04% |
| Dec 31, 2023 | 1,034.68% |
| Sep 30, 2023 | -75.10% |
| Jun 30, 2023 | -115.64% |
| Mar 31, 2023 | 1,677.36% |
| Dec 31, 2022 | -173.17% |
| Sep 30, 2022 | 47.03% |
| Jun 30, 2022 | -200.34% |
| Mar 31, 2022 | -116.41% |
| Dec 31, 2021 | 116.66% |
| Sep 30, 2021 | -227.86% |